



Research review paper

ABCs of DNA aptamer and related assay development

Tarun Kumar Sharma^{a,b,*}, John G. Bruno^{c,**}, Abhijeet Dhiman^{d,e}^a Center for Biodesign and Diagnostics, Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India^b AptaBharat Innovation Private Limited, Translational Health Science and Technology Institute Incubator, Haryana 121001, India^c Operational Technologies Corporation, 4100 NW Loop 410, Suite, 230, San Antonio, TX 78229, USA.^d Department of Biotechnology, All India Institute of Medical Sciences, New Delhi 110029, India.^e Faculty of Pharmacy, Uttarakhand Technical University, Dehradun 248007, Uttarakhand, India

ARTICLE INFO

Article history:

Received 23 August 2016

Received in revised form 19 November 2016

Accepted 17 January 2017

Available online 18 January 2017

Keywords:

Aptamers

SELEX

Aptamer library

Colorimetric assay

Aptamer Linked Immunosorbent Assay (ALISA)

FRET

ssDNA generation

Post-SELEX optimization

Translation of aptamers

ABSTRACT

This review is intended to guide the novice in aptamer research and development to understand virtually all of the aptamer development options and currently available assay modalities. Aptamer development topics range from discussions of basic and advanced versions of Systematic Evolution of Ligands by EXponential Enrichment (SELEX) and SELEX variations involving incorporation of exotic unnatural nucleotides to expand library diversity for even greater aptamer affinity and specificity to improved next generation methods of DNA sequencing, screening and tracking aptamer development throughout the SELEX process and characterization of lead aptamer candidates. Aptamer assay development topics include descriptions of various colorimetric and fluorescent assays in microplates or on membranes including homogeneous beacon and multiplexed Fluorescence Resonance Energy Transfer (FRET) assays. Finally, a discussion of the potential for marketing successful aptamer-based assays or test kits is included.

© 2017 Elsevier Inc. All rights reserved.

Contents

1.	Introduction	276
2.	Library design	276
2.1.	First generation	276
2.2.	Second generation	278
3.	PCR issues and single-stranded DNA (ssDNA) generation	279
3.1.	Methods of making ssDNA	279
3.1.1.	Asymmetric PCR	279
3.1.2.	Bead-based separation	280
3.1.3.	Ribolinkage based separation	282
3.1.4.	Enzymatic separation	282
3.1.5.	Specially designed primers for the generation of PCR products with strands of unequal length.	282
4.	Immobilization of target.	282
5.	SELEX variants - which one to choose?	284
6.	Cloning	284
7.	Sequencing	284
8.	Evaluation and characterization of putative aptamers.	284
8.1.	Colorimetric assays.	284
8.1.1.	Aptamer Linked Immunosorbent Assay (ALISA) and dot-blot assays.	286
8.1.2.	Rolling circle amplification (RCA) based colorimetric assays	286

* Correspondence to: T. K. Sharma, Centre for Biodesign and Diagnostics, Translational Health Science and Technology Institute, Faridabad, Haryana 121001, India.

** Correspondence to: J. G. Bruno, Operational Technologies Corporation, 4100 NW Loop 410, Suite 230, San Antonio, TX 78229, USA.

E-mail addresses: tarun@thsti.res.in (T.K. Sharma), john.bruno@otcorp.com (J.G. Bruno).

8.1.3.	Gold nanoparticles (GNPs) aggregation assays	287
8.1.4.	Nanozyme-mediated turn-off/turn-on approach for aptamer screening	287
8.2.	Fluorescence-based assays	287
8.2.1.	Single label assays	287
8.2.2.	FRET-based aptamer assays	289
8.3.	Gel-based evaluation and characterization of aptamers	290
8.4.	Biophysical characterization	290
8.5.	Thermal shift assay	291
8.6.	UV-visible melting profiles	291
8.7.	Computational tools to predict aptamer structure and analysis of high throughput sequencing data	291
9.	Post-SELEX optimization	292
9.1.	Truncation	292
9.2.	Chemical modifications	292
9.3.	Construction of bivalent and multivalent aptamers	293
9.4.	Affinity improvement through random mutations, site-directed mutagenesis and in silico maturation	293
10.	Aptamer success stories	294
11.	Translation of aptamers to products	294
12.	Concluding remarks	294
	Conflict of interest	296
	Acknowledgments	296
	References	296

1. Introduction

Jayasena predicted in 1999 that aptamers would rival antibodies in diagnostics and therapeutics (Jayasena, 1999), and despite a few clear successes in the forms of Macugen and ultrasensitive aptamers (Vance and Sandros, 2014), or SOMAmer-based proteomic chips (Kraemer et al., 2011) and a few other commercial assays (Penner, 2012), the potential of aptamers is yet to be reached. However, aptamers offer clear advantages over antibodies including, but not limited to, greater batch to batch reproducibility, speed, lower cost, ease of development, obviating the use of host animals (Chopra et al., 2014; Lange et al., 2012; Sharma and Shukla, 2014a, 2014b). Researchers continue to innovate the SELEX (Systematic Evolution of Ligands by EXponential enrichment) process itself as well as developing novel assay formats in which only aptamers can work or work clearly better than their antibody competitors (Chopra et al., 2014; Lange et al., 2012; Sharma and Shukla, 2014a, 2014b). An example of a system in which aptamers can exclude antibodies in competition are conformation-dependent electrochemical systems in which the changes in aptamer 3-dimensional conformations lead to detectable changes in conduction or voltammetry (Catanante et al., 2016). Another example of aptamers working better than antibodies is multiplexed FRET assays in which aptamer-quantum dot (QD) conjugates adsorbed onto gold nanoparticles (GNPs) are liberated by greater affinity for target analytes in solution leading to multicolored or multiple fluorescence emission wavelengths with a single ultraviolet light source (Kim and Jung, 2011; Zhang et al., 2010).

While many researchers continue to use aptamers in conventional antibody-based immunoassay formats such as ELISA-like assays or lateral flow chromatographic test strips, the more creative approaches may lead to the real future commercial product breakthrough. Though there are several published reviews underlining the importance of SELEX and application of aptamers, none, comprehensively summarize every single step of SELEX from library design to post-SELEX optimization to assay development. In the following work, the authors have endeavored to summarize the basic steps and more recent advanced developments in SELEX and aptamer assays to aid current and future innovators and to help aptamers realize their full potential especially in the diagnostics area. An overall picture of aptamer technology (SELEX) is portrayed in Fig. 1.

2. Library design

2.1. First generation

The design of the starting randomized nucleic acid library provides the basis for SELEX. A variety of SELEX libraries are used across the




Fig. 1. Flow chart showing overall picture of SELEX technology.

Download English Version:

<https://daneshyari.com/en/article/4752554>

Download Persian Version:

<https://daneshyari.com/article/4752554>

[Daneshyari.com](https://daneshyari.com)